Perforating pilomatricoma presenting as a cutaneous horn in a patient with myotonic dystrophy

EJD, vol. 32, n◦ 2, March-April 2022 were all reliable indices of disease activity. For BP, titre of anti-BP180 reflected clinical activity; therefore, we consider it useful in monitoring disease activity during follow-up. Conversely, IIF positivity, titre of anti-BP-230 and variation of titres with time did not parallel disease activity. An interesting novelty is that, in our small sample, when remission is achieved, antibody titre cannot be considered a predictor of relapse of AIBD. Therefore, considerations for therapy should not rely on this titre. Surely, these findings need to be confirmed in larger, multicentric studies. We are also continuing clinical and serological follow-up for these patients. To answer our initial question: although some serological markers may overlap with disease activity, in our opinion, the clinical picture should guide our therapeutic decisions.